60219-2280-2 : NDC 2026 Code

60219-2280-2 : Everolimus ( Everolimus )

Additionally :

You can get information about “60219-2280-2” NDC code in 60219-2280-2 in HTML format

HTML | 60219-2280-2 in TXT (Plain Text) format

TXT | 60219-2280-2 in PDF (Portable Document Format)

PDF | 60219-2280-2 in XML format

XML formats.

NDC Code : 60219-2280-2 – JSON Data Format

                
{
  "NDC": {
    "NDCCode": "60219-2280-2",
    "PackageDescription": "4 BLISTER PACK in 1 CARTON (60219-2280-2)  / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK (60219-2280-1) ",
    "NDC11Code": "60219-2280-02",
    "ProductNDC": "60219-2280",
    "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
    "ProprietaryName": "Everolimus",
    "ProprietaryNameSuffix": null,
    "NonProprietaryName": "Everolimus",
    "DosageFormName": "TABLET, FOR SUSPENSION",
    "RouteName": "ORAL",
    "StartMarketingDate": "20250114",
    "EndMarketingDate": null,
    "MarketingCategoryName": "ANDA",
    "ApplicationNumber": "ANDA218863",
    "LabelerName": "Amneal Pharmaceuticals NY LLC",
    "SubstanceName": "EVEROLIMUS",
    "StrengthNumber": "3",
    "StrengthUnit": "mg/1",
    "Pharm_Classes": "Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",
    "DEASchedule": null,
    "Status": "Active",
    "LastUpdate": "2025-01-14",
    "PackageNdcExcludeFlag": "N",
    "ProductNdcExcludeFlag": "N",
    "ListingRecordCertifiedThrough": "20261231",
    "StartMarketingDatePackage": "20250114",
    "EndMarketingDatePackage": null,
    "SamplePackage": "N"
  }
}